Data Analysis Shows Significant New Onset Morbidity Post-COVID-19 in Children, Adolescents, Adults
November 21, 2022 03:23pm
By Jill Murphy, Associate Editor
A study recently published in the Journal of Infectious Diseases indicated that an estimated 200,000 lives could be saved over the next 2 decades if the National HIV/AIDS Strategy targets are achieved.
A study recently published in theJournal of Infectious Diseasesindicated that an estimated 200,000 lives could be saved over the next 2 decades if the National HIV/AIDS Strategy targets are achieved.
are for 90% of HIV-positive individuals to know their diagnosis, and for 80% of those patients to achieve virologic suppression via antiretroviral therapy (ART) by 2020.
In a study published in the
, Massachusetts General Hospital (MGH) analysts found that meeting the goals of NHAS would save more than 2 million years of life over the next 2 decades.
Journal of Infectious Diseases
“If nearly everyone with HIV in the US were in care, on medication, and virally suppressed, we would stop the epidemic in its tracks,” said senior author Rochelle P. Walensky, MD, MPH, chief of the MGH Division of Infectious Diseases. “Achieving the NHAS goals would bring us one step closer to that goal.”
The NHAS was released in 2015 to better align US HIV/AIDS policies with the Joint United Nations Programme on HIV/AIDS
, which states that by 2020, 90% of all individuals living with HIV will know their status, 90% of HIV-positive individuals will receive sustained ART, and 90% of all individuals receiving ART will achieve viral suppression.
If the NHAS targets are met, 72% of HIV-positive individuals would successfully achieve virologic suppression compared with current estimates of 49%.
An estimated 1.1 million individuals in the United States are living with HIV, and 1 of every 7 are unaware of their status. According to the CDC, men who have sex with men (
) and bisexual men are most affected, particularly African Americans.
For the study, MGH investigators sought to identify the expected return on investment for the programs required to achieve NHAS goals, and to highlight the impact that failing to achieve the goals would have on illness and death. A separate analysis was conducted on the impact of NHAS among
The investigators used a mathematical model to assess the cost efficacy of HIV/AIDS prevention, and compared the forecasted results of continuing at the current pace of HIV diagnosis, linkage to and retention in treatment, and viral suppression to achieving NHAS goals. They projected both the clinical benefits and costs over a 20-year period.
The findings showed that if the United States remained at its current pace, then 750,000 deaths from HIV/AIDS would occur over 20 years. Contrastingly, if NHAS goals were achieved, it would reduce total deaths to 551,000, preventing approximately 200,000 deaths.
Among the black MSM patient population, achieving NHAS targets would reduce the number of deaths from 110,000 to 65,000.
“Achieving NHAS goals is entirely feasible,” said co-author Kenneth Freedberg, MD, MSc. “One of the biggest barriers is retaining patients in care, but our projections would be enough to reach these goals. This study is only the latest contribution to the large evidence base demonstrating conclusively that we have it in our clinical and economic power to bring the HIV/AIDS epidemic in the US to a halt. Now is the time to do so.”
Over the next 20 years, meeting NHAS targets would cost an estimated $645.7 billion compared with $525.3 billion under the current pace; however, the number of lives saved would result in a cost effectiveness ratio of $68,900 per quality-adjusted life year (QALY). According to the authors, this is well within the US cost effectiveness standard of 100,000/QALY.
Findings from the separate analysis of the black MSM population revealed that achieving the NHAS targets would produce a ratio of $38,300/QALY.
The authors noted that reducing the cost of ART could lead to even greater cost effectiveness because almost 75% of costs are attributable to ART.
“Achieving NHAS won’t be cheap, but it would be affordable and cost effective,” Freedberg said. “It would make good public health and economic sense to first focus NHAS implementation on black MSM, since they are at considerably higher risk than the general population. Overall, fully implementing NHAS could avert more than 200,000 deaths and prevent more than 250,000 HIV infections over the next 20 years.”
This article originally appeared onSpecialty Pharmacy Times.